Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

CG Oncology

NASDAQ: CGON ↗$79.47 USD$7.52B MCAP

CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy, for non-muscle invasive bladder cancer. Its Phase 3 program spans BOND-003 in BCG-unresponsive disease and PIVOT-006 as adjuvant monotherapy in intermediate-risk disease following TURBT, with earlier studies exploring high-risk and BCG-naïve populations.

Company Info

Sector:Oncology / Clinical-Stage Biotech
Headquarters:Dallas, TX, USA
Founded:2010

Clinical Development Pipeline

Cretostimogene grenadenorepvec

Target: Oncolytic adenovirus immunotherapy
Intermediate-risk non-muscle invasive bladder cancer (adjuvant monotherapy after TURBT)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Cretostimogene grenadenorepvec

Target: Oncolytic adenovirus immunotherapy
BCG-unresponsive high-risk non-muscle invasive bladder cancer
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Cretostimogene grenadenorepvec

Target: Oncolytic adenovirus immunotherapy
High-risk non-muscle invasive bladder cancer, BCG-exposed and BCG-naïve
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Arthur Kuan

Chief Executive Officer

Careers & Job Openings

See all open roles

Clinical Operations / Commercial
Dallas, TX
Apply Now →